Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1992 Sep;34(5):349–354. doi: 10.1007/BF01741557

Allogeneic tumor-specific cytotoxic T lymphocytes

Joan M Redd 1, Anne-Catherine Lagarde 1, Carol A Kruse 2, Donald Bellgrau 1,
PMCID: PMC11038263  PMID: 1371720

Abstract

We report the development of cytotoxic T lymphocytes specific for an allogeneic brain tumor in a rat model. DA strain cytotoxic T cell precursors stimulated by an allogeneic tumor (9L gliosarcoma) from the Fischer rat could generate a population of cytotoxic T lymphocytes that lysed the allogeneic 9L tumor but failed to lyse other targets, including Fischer concanavalin-A(ConA)-stimulated lymphoid blast targets. DA T cells depleted of reactivity to the Fischer haplotype (DA-f) retained reactivity to the 9L tumor, demonstrating that T cell precursors with specificity for normal Fischer alloantigens were not required for the generation of a response to the 9L Fischer tumor. The preferential lysis of the tumor target did not simply reflect a higher density of Fischer target antigens on the tumor than that found on normal Fischer ConA blast targets. First, the relative densities of class I antigen on the 9L tumor and normal Fischer ConA blasts were comparable. Second, cytotoxic T cells could not be generated from DA-f precursors when Fischer ConA blasts were used as stimulators. If DA-f T cells were simply responding to the higher density of Fischer antigen found on 9L tumor, it would have been expected that the ConA blasts expressing comparable levels of antigen to that found on the tumor would have generated cytotoxicity for both the 9L and ConA targets. We conclude that the cytotoxic T cells are specific for a determinant expressed only by the tumor. Such tumor-specific cytotoxic T cells could be useful in vivo for adoptive immunotherapy of brain tumors.

Key words: Immunotherapy, Glioma, Activated lymphocytes

References

  • 1.Albright AL, Gill TJ, Geyer SJ. Immunogenetic control of brain tumor growth in rats. Cancer Res. 1977;27:2512. [PubMed] [Google Scholar]
  • 2.Bellgrau D. Induction of cytotoxic T cell precursors in vivo. Role of T helper cells. J Exp Med. 1983;157:1505. doi: 10.1084/jem.157.5.1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bellgrau D, Lagarde A-C. In vivo separation of two classes of T cells as determined by negative selection after the injection of uv-treated allogeneic lymphoid cells. Proc Natl Acad Sci USA. 1985;82:5136. doi: 10.1073/pnas.82.15.5136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bellgrau D, Lagarde A-C. Cytotoxic T cell precursors with low level CD8 in the diabetes-prone Biobreeding rat: implications for generation of an autoimmune T-cell repertoire. Proc Natl Acad Sci USA. 1990;87:313. doi: 10.1073/pnas.87.1.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bellgrau D, Talmage DW. T cells can be cytotoxic without making Interleukin 1: a model of separate pathways of induction. Proc Natl Acad Sci USA. 1986;83:3412. doi: 10.1073/pnas.83.10.3412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bellgrau D, Zoller M. Cytotoxic T lymphocyte responses to spontaneous tumors: immunogenicity dependent on the recognition of processed tumor antigens. J Immunol. 1983;130:2005. [PubMed] [Google Scholar]
  • 7.Bennick JR, Doherty PC. Different rules govern help for cytotoxic T cells and B cells. Nature. 1978;276:829. doi: 10.1038/276829a0. [DOI] [PubMed] [Google Scholar]
  • 8.Bhondeley MK, Mehra RD, Mehra NK, Mohapatra AK, Tandon PN, Roy S, Bijlani V. Imbalances in T cell subpopulations in human gliomas. J Neurosurg. 1988;68:589. doi: 10.3171/jns.1988.68.4.0589. [DOI] [PubMed] [Google Scholar]
  • 9.Chiu KM, Harris JE, Droin JS, Slayton W, Braun DP. The immunological response of Wistar rats to the intracranially implanted C-6 glioma cell line. J Neurooncol. 1983;1:365. doi: 10.1007/BF00165720. [DOI] [PubMed] [Google Scholar]
  • 10.Dorsch S, Roser B. T cells mediate transplantation tolerance. Nature. 1975;258:233. doi: 10.1038/258233a0. [DOI] [PubMed] [Google Scholar]
  • 11.Fischer-Lindahl K, Wilson DB. Histocompatibility antigen-activated cytotoxic T lymphocytes II. Estimates of the frequency and specificity of precursors. J Exp Med. 1977;145:508. doi: 10.1084/jem.145.3.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fontana A, Hengartner H, deTribolet N, Weber E. Glioblastoma cells release Interleukin 1 and factors inhibiting interleukin-2-mediated effects. J Immunol. 1984;132:1837. [PubMed] [Google Scholar]
  • 13.Fuchs HE, Bullard DE. Immunology of transplantation in the central nervous system. Appl Neurophysiol. 1988;51:278. doi: 10.1159/000099973. [DOI] [PubMed] [Google Scholar]
  • 14.Gately MK, Glaser M, Dick SJ, Mettetal RW, Kornblith PL. In vitro studies on the cell-mediated immune response to human brain tumor I. Requirement for third party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas. JNCI. 1982;69:1245. [PubMed] [Google Scholar]
  • 15.Geyer SJ, Landry A. Immunogenetic and immunologic aspects of gliosarcoma growth in rats. Lab Invest. 1983;49:436. [PubMed] [Google Scholar]
  • 16.Gowans JL. The fate of parental strain small lymphocytes in F1 hybrid rats. Ann NY Acad Sci. 1962;99:432. doi: 10.1111/j.1749-6632.1962.tb45326.x. [DOI] [PubMed] [Google Scholar]
  • 17.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Heath WR, Hurd ME, Carbone FR, Sherman LA. Peptide-dependent recognition of H-2Kb by alloreactive cytotoxic T lymphocytes. Nature. 1989;341:749. doi: 10.1038/341749a0. [DOI] [PubMed] [Google Scholar]
  • 19.Ingram M, Buckwalter JG, Jacques DB, Freshwater DB, Abts RM, Techy GB, Migagi K, Shelden CH, Rand RW, English LW. Immunotherapy for recurrent malignant glioma: an interim report on survival. Neurol Res. 1990;12:265. doi: 10.1080/01616412.1990.11739955. [DOI] [PubMed] [Google Scholar]
  • 20.Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL, Grimm EA. Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies. Neurol Res. 1986;8:81. doi: 10.1080/01616412.1986.11739735. [DOI] [PubMed] [Google Scholar]
  • 21.Kruse CA, Mitchell DH, Lillehei DO, Johnson SD, McCleary L, Moore GE, Waldrop S, Mierau GW. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer. 1989;64:1629. doi: 10.1002/1097-0142(19891015)64:8<1629::aid-cncr2820640813>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  • 22.Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-Demasters B, Bellgrau D. Analysis of Interleukin-2 and various effector cell populations in adoptive immunotherapy of 9L gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci USA. 1990;87:9577. doi: 10.1073/pnas.87.24.9577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (rIL2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenosarcoma. J Immunol. 1985;135:4273. [PubMed] [Google Scholar]
  • 24.Lillehei KO, Kruse CA, Mitchell DH, Johnson SD, McCleary EL. Adoptive immunotherapy of recurrent glioma using interleukin-2-stimulated lymphocytes. Surg Forum. 1989;40:493. [Google Scholar]
  • 25.Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA. Long-term follow-up of patients with recurrent gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery. 1991;28:16. doi: 10.1097/00006123-199101000-00003. [DOI] [PubMed] [Google Scholar]
  • 26.Marrack P, Kappler J. T cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature. 1990;332:840. doi: 10.1038/332840a0. [DOI] [PubMed] [Google Scholar]
  • 27.Medewar PB. Immunity to homologous grafted skin: III. The fate of skin homografts transplanted to the brain, to subcutaneous tissues, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58. [PMC free article] [PubMed] [Google Scholar]
  • 28.Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer. 1988;62:666–671. doi: 10.1002/1097-0142(19880815)62:4<665::aid-cncr2820620403>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  • 29.Merchant RE, Ellison MD, Young HF. Immunotherapy for malignant glioma using human recombinant interleukin 2 and activated autologous lymphocytes. J Neurooncol. 1990;8:173. doi: 10.1007/BF00177842. [DOI] [PubMed] [Google Scholar]
  • 30.Molina IJ, Huber BT. The expression of a tissue-specific self peptide is required for allorecognition. J Immunol. 1990;144:2082. [PubMed] [Google Scholar]
  • 31.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and Interleukin-2 or high-dose Interleukin-2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 32.Salcman M. Epidemiology and factors for survival. In: Apuzzo UJL, editor. Malignant cerebral glioma. Park Ridge: American Association of Neurosurgery; 1990. p. 95. [Google Scholar]
  • 33.Wilson DB, Marshak A, Howard JC. Specific positive and negative selection of rat lymphocytes reactive to strong histocompatibility antigens: activation with alloantigens in vitro and in vivo. J Immunol. 1976;115:1030. [PubMed] [Google Scholar]
  • 34.Wilson DB, Fischer-Lindahl K, Wilson D, Sprent J. The generation of killer cells to TNP modified allogeneic targets by lymphocyte populations negatively selected to strong alloantigens. J Exp Med. 1977;146:361. doi: 10.1084/jem.146.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zoller M, Bellgrau D, Axberg I, Wigzell H. Natural killer cells do not belong to the recirculating lymphocyte pool. Scand J Immunol. 1982;15:159. doi: 10.1111/j.1365-3083.1982.tb00634.x. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES